Drugs / CDR404
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06402201 | May 2024 → Jun 2026 overdue | cancer | CDR-Life AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-10-23 | CDR-Life AG | Results CDR-Life Presents Early Clinical Data Demonstrating Pharmacodynamic Activity of CDR404, a Novel Antibody-Derived T Cell Engager Targeting MAGE-A4+ Solid Tumors cdr-life.com ↗
The data, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, in Boston, Massachusetts, highlights CDR404’s robust immune activation and early signals of clinical activity, including tumor stabilization and biomarker improvements in patients with ovarian cancers and synovial sarcomas. |
| 2025-04-25 | CDR-Life AG | Results CDR-Life Presents Promising Preclinical Data for Novel T Cell Engager Programs at AACR Annual Meeting 2025 cdr-life.com ↗
CDR404 demonstrated superior potency and durability in preclinical models, which align with the encouraging early signals we’re seeing in our ongoing Phase 1 trial. |
| 2024-01-23 | CDR-Life AG | Regulatory CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors cdr-life.com ↗
CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CDR404, its lead program in development as a precision immunotherapy for solid tumors. |
| 2023-11-03 | CDR-Life AG | Results CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023 cdr-life.com ↗
The demonstration of high MAGE-A4 protein expression in SQ-NSCLC and potent preclinical cytotoxicity of CDR404, highlights the therapeutic promise of CDR404 in HLA-A*02:01+ patients with SQ-NSCLC. |
| 2023-10-23 | CDR-Life AG | Results CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023 cdr-life.com ↗
TCGA bioinformatic analyses revealed that squamous cell cancers were enriched for high levels of MAGE-A4 mRNA expression including squamous NSCLC, head and neck carcinoma associated with absence of human papillomavirus (HPV) infection, and bladder cancer. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDR404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06402201 ↗ |
| Route | Intravenous | “IV infusions” NCT06402201 ↗ |